<?xml version='1.0' encoding='utf-8'?>
<document id="25789542"><sentence text="Prevention of dipyrone (metamizole) induced inhibition of aspirin antiplatelet effects."><entity charOffset="14-22" id="DDI-PubMed.25789542.s1.e0" text="dipyrone" /><entity charOffset="24-34" id="DDI-PubMed.25789542.s1.e1" text="metamizole" /><entity charOffset="58-65" id="DDI-PubMed.25789542.s1.e2" text="aspirin" /><pair ddi="false" e1="DDI-PubMed.25789542.s1.e0" e2="DDI-PubMed.25789542.s1.e0" /><pair ddi="false" e1="DDI-PubMed.25789542.s1.e0" e2="DDI-PubMed.25789542.s1.e1" /><pair ddi="false" e1="DDI-PubMed.25789542.s1.e0" e2="DDI-PubMed.25789542.s1.e2" /><pair ddi="false" e1="DDI-PubMed.25789542.s1.e1" e2="DDI-PubMed.25789542.s1.e1" /><pair ddi="false" e1="DDI-PubMed.25789542.s1.e1" e2="DDI-PubMed.25789542.s1.e2" /></sentence><sentence text="We have recently shown that dipyrone (metamizole), a non-opioid analgesic, can nullify aspirin (acetylsalicylic acid; ASA) antiplatelet effects in patients with coronary artery disease (CAD)"><entity charOffset="28-36" id="DDI-PubMed.25789542.s2.e0" text="dipyrone" /><entity charOffset="38-48" id="DDI-PubMed.25789542.s2.e1" text="metamizole" /><entity charOffset="87-94" id="DDI-PubMed.25789542.s2.e2" text="aspirin" /><entity charOffset="96-116" id="DDI-PubMed.25789542.s2.e3" text="acetylsalicylic acid" /><entity charOffset="118-121" id="DDI-PubMed.25789542.s2.e4" text="ASA" /><pair ddi="false" e1="DDI-PubMed.25789542.s2.e0" e2="DDI-PubMed.25789542.s2.e0" /><pair ddi="false" e1="DDI-PubMed.25789542.s2.e0" e2="DDI-PubMed.25789542.s2.e1" /><pair ddi="false" e1="DDI-PubMed.25789542.s2.e0" e2="DDI-PubMed.25789542.s2.e2" /><pair ddi="false" e1="DDI-PubMed.25789542.s2.e0" e2="DDI-PubMed.25789542.s2.e3" /><pair ddi="false" e1="DDI-PubMed.25789542.s2.e0" e2="DDI-PubMed.25789542.s2.e4" /><pair ddi="false" e1="DDI-PubMed.25789542.s2.e1" e2="DDI-PubMed.25789542.s2.e1" /><pair ddi="false" e1="DDI-PubMed.25789542.s2.e1" e2="DDI-PubMed.25789542.s2.e2" /><pair ddi="false" e1="DDI-PubMed.25789542.s2.e1" e2="DDI-PubMed.25789542.s2.e3" /><pair ddi="false" e1="DDI-PubMed.25789542.s2.e1" e2="DDI-PubMed.25789542.s2.e4" /><pair ddi="false" e1="DDI-PubMed.25789542.s2.e2" e2="DDI-PubMed.25789542.s2.e2" /><pair ddi="false" e1="DDI-PubMed.25789542.s2.e2" e2="DDI-PubMed.25789542.s2.e3" /><pair ddi="false" e1="DDI-PubMed.25789542.s2.e2" e2="DDI-PubMed.25789542.s2.e4" /><pair ddi="false" e1="DDI-PubMed.25789542.s2.e3" e2="DDI-PubMed.25789542.s2.e3" /><pair ddi="false" e1="DDI-PubMed.25789542.s2.e3" e2="DDI-PubMed.25789542.s2.e4" /></sentence><sentence text=" In this study, we analysed the aspirin and dipyrone drug-drug interaction in order to identify strategies to prevent the dipyrone induced inhibition of asprin antiplatelet effects"><entity charOffset="32-39" id="DDI-PubMed.25789542.s3.e0" text="aspirin" /><entity charOffset="44-52" id="DDI-PubMed.25789542.s3.e1" text="dipyrone" /><entity charOffset="122-130" id="DDI-PubMed.25789542.s3.e2" text="dipyrone" /><pair ddi="false" e1="DDI-PubMed.25789542.s3.e0" e2="DDI-PubMed.25789542.s3.e0" /><pair ddi="false" e1="DDI-PubMed.25789542.s3.e0" e2="DDI-PubMed.25789542.s3.e1" /><pair ddi="false" e1="DDI-PubMed.25789542.s3.e0" e2="DDI-PubMed.25789542.s3.e2" /><pair ddi="false" e1="DDI-PubMed.25789542.s3.e1" e2="DDI-PubMed.25789542.s3.e1" /><pair ddi="false" e1="DDI-PubMed.25789542.s3.e1" e2="DDI-PubMed.25789542.s3.e2" /></sentence><sentence text=" Platelet function was measured by arachidonic acid-induced light-transmission aggregometry, thromboxane (TX) B2- formation by immunoassay"><entity charOffset="35-51" id="DDI-PubMed.25789542.s4.e0" text="arachidonic acid" /><entity charOffset="93-104" id="DDI-PubMed.25789542.s4.e1" text="thromboxane" /><pair ddi="false" e1="DDI-PubMed.25789542.s4.e0" e2="DDI-PubMed.25789542.s4.e0" /><pair ddi="false" e1="DDI-PubMed.25789542.s4.e0" e2="DDI-PubMed.25789542.s4.e1" /></sentence><sentence text=" Dipyrone metabolite plasma levels were determined by high-performance-liquid-chromatography (HPLC)"><entity charOffset="1-9" id="DDI-PubMed.25789542.s5.e0" text="Dipyrone" /></sentence><sentence text=" In seven healthy individuals, in vitro ASA (30 µM/ 100 µM/ 300 µM/ 1,000 µM) and dipyrone (10 µM) coincubation revealed, that the aspirin and dipyrone interaction can be overcome by increasing doses of aspirin"><entity charOffset="82-90" id="DDI-PubMed.25789542.s6.e0" text="dipyrone" /><entity charOffset="131-138" id="DDI-PubMed.25789542.s6.e1" text="aspirin" /><entity charOffset="143-151" id="DDI-PubMed.25789542.s6.e2" text="dipyrone" /><entity charOffset="203-210" id="DDI-PubMed.25789542.s6.e3" text="aspirin" /><entity charOffset="40-46" id="DDI-PubMed.25789542.s6.e4" text="ASA" /><pair ddi="false" e1="DDI-PubMed.25789542.s6.e4" e2="DDI-PubMed.25789542.s6.e4" /><pair ddi="false" e1="DDI-PubMed.25789542.s6.e4" e2="DDI-PubMed.25789542.s6.e0" /><pair ddi="false" e1="DDI-PubMed.25789542.s6.e4" e2="DDI-PubMed.25789542.s6.e1" /><pair ddi="false" e1="DDI-PubMed.25789542.s6.e4" e2="DDI-PubMed.25789542.s6.e2" /><pair ddi="false" e1="DDI-PubMed.25789542.s6.e4" e2="DDI-PubMed.25789542.s6.e3" /><pair ddi="false" e1="DDI-PubMed.25789542.s6.e0" e2="DDI-PubMed.25789542.s6.e0" /><pair ddi="false" e1="DDI-PubMed.25789542.s6.e0" e2="DDI-PubMed.25789542.s6.e1" /><pair ddi="false" e1="DDI-PubMed.25789542.s6.e0" e2="DDI-PubMed.25789542.s6.e2" /><pair ddi="false" e1="DDI-PubMed.25789542.s6.e0" e2="DDI-PubMed.25789542.s6.e3" /><pair ddi="false" e1="DDI-PubMed.25789542.s6.e1" e2="DDI-PubMed.25789542.s6.e1" /><pair ddi="false" e1="DDI-PubMed.25789542.s6.e1" e2="DDI-PubMed.25789542.s6.e2" /><pair ddi="false" e1="DDI-PubMed.25789542.s6.e1" e2="DDI-PubMed.25789542.s6.e3" /><pair ddi="false" e1="DDI-PubMed.25789542.s6.e2" e2="DDI-PubMed.25789542.s6.e2" /><pair ddi="false" e1="DDI-PubMed.25789542.s6.e2" e2="DDI-PubMed.25789542.s6.e3" /></sentence><sentence text=" In 36 aspirin and dipyrone comedicated CAD patients, addition of ASA (30 µM/ 100 µM) in vitro inhibited, but did not completely overcome the dipyrone induced reduction of aspirin antiplatelet effects"><entity charOffset="7-14" id="DDI-PubMed.25789542.s7.e0" text="aspirin" /><entity charOffset="19-27" id="DDI-PubMed.25789542.s7.e1" text="dipyrone" /><entity charOffset="142-150" id="DDI-PubMed.25789542.s7.e2" text="dipyrone" /><entity charOffset="172-179" id="DDI-PubMed.25789542.s7.e3" text="aspirin" /><entity charOffset="66-72" id="DDI-PubMed.25789542.s7.e4" text="ASA" /><pair ddi="false" e1="DDI-PubMed.25789542.s7.e0" e2="DDI-PubMed.25789542.s7.e0" /><pair ddi="false" e1="DDI-PubMed.25789542.s7.e0" e2="DDI-PubMed.25789542.s7.e1" /><pair ddi="false" e1="DDI-PubMed.25789542.s7.e0" e2="DDI-PubMed.25789542.s7.e4" /><pair ddi="false" e1="DDI-PubMed.25789542.s7.e0" e2="DDI-PubMed.25789542.s7.e2" /><pair ddi="false" e1="DDI-PubMed.25789542.s7.e0" e2="DDI-PubMed.25789542.s7.e3" /><pair ddi="false" e1="DDI-PubMed.25789542.s7.e1" e2="DDI-PubMed.25789542.s7.e1" /><pair ddi="false" e1="DDI-PubMed.25789542.s7.e1" e2="DDI-PubMed.25789542.s7.e4" /><pair ddi="false" e1="DDI-PubMed.25789542.s7.e1" e2="DDI-PubMed.25789542.s7.e2" /><pair ddi="false" e1="DDI-PubMed.25789542.s7.e1" e2="DDI-PubMed.25789542.s7.e3" /><pair ddi="false" e1="DDI-PubMed.25789542.s7.e4" e2="DDI-PubMed.25789542.s7.e4" /><pair ddi="false" e1="DDI-PubMed.25789542.s7.e4" e2="DDI-PubMed.25789542.s7.e2" /><pair ddi="false" e1="DDI-PubMed.25789542.s7.e4" e2="DDI-PubMed.25789542.s7.e3" /><pair ddi="false" e1="DDI-PubMed.25789542.s7.e2" e2="DDI-PubMed.25789542.s7.e2" /><pair ddi="false" e1="DDI-PubMed.25789542.s7.e2" e2="DDI-PubMed.25789542.s7.e3" /></sentence><sentence text=" Notably, the inhibition of thromboxane formation in aspirin and dipyrone comedicated CAD patients coincided with dipyrone plasma levels"><entity charOffset="28-39" id="DDI-PubMed.25789542.s8.e0" text="thromboxane" /><entity charOffset="53-60" id="DDI-PubMed.25789542.s8.e1" text="aspirin" /><entity charOffset="65-73" id="DDI-PubMed.25789542.s8.e2" text="dipyrone" /><entity charOffset="114-122" id="DDI-PubMed.25789542.s8.e3" text="dipyrone" /><pair ddi="false" e1="DDI-PubMed.25789542.s8.e0" e2="DDI-PubMed.25789542.s8.e0" /><pair ddi="false" e1="DDI-PubMed.25789542.s8.e0" e2="DDI-PubMed.25789542.s8.e1" /><pair ddi="false" e1="DDI-PubMed.25789542.s8.e0" e2="DDI-PubMed.25789542.s8.e2" /><pair ddi="false" e1="DDI-PubMed.25789542.s8.e0" e2="DDI-PubMed.25789542.s8.e3" /><pair ddi="false" e1="DDI-PubMed.25789542.s8.e1" e2="DDI-PubMed.25789542.s8.e1" /><pair ddi="false" e1="DDI-PubMed.25789542.s8.e1" e2="DDI-PubMed.25789542.s8.e2" /><pair ddi="false" e1="DDI-PubMed.25789542.s8.e1" e2="DDI-PubMed.25789542.s8.e3" /><pair ddi="false" e1="DDI-PubMed.25789542.s8.e2" e2="DDI-PubMed.25789542.s8.e2" /><pair ddi="false" e1="DDI-PubMed.25789542.s8.e2" e2="DDI-PubMed.25789542.s8.e3" /></sentence><sentence text=" In a cross-over designed study in four healthy individuals, we were able to prove that inhibition of aspirin (100 mg/ day) effects by dipyrone (750 mg/ day) was reversible"><entity charOffset="102-109" id="DDI-PubMed.25789542.s9.e0" text="aspirin" /><entity charOffset="135-143" id="DDI-PubMed.25789542.s9.e1" text="dipyrone" /><pair ddi="false" e1="DDI-PubMed.25789542.s9.e0" e2="DDI-PubMed.25789542.s9.e0" /><pair ddi="false" e1="DDI-PubMed.25789542.s9.e0" e2="DDI-PubMed.25789542.s9.e1" /></sentence><sentence text=" Furthermore, aspirin (100 mg/ day) medication prior to dipyrone (750 mg/ day) intake prevented the inhibition of antiplatelet effects by dipyrone in 12 healthy individuals"><entity charOffset="14-21" id="DDI-PubMed.25789542.s10.e0" text="aspirin" /><entity charOffset="56-64" id="DDI-PubMed.25789542.s10.e1" text="dipyrone" /><entity charOffset="138-146" id="DDI-PubMed.25789542.s10.e2" text="dipyrone" /><pair ddi="false" e1="DDI-PubMed.25789542.s10.e0" e2="DDI-PubMed.25789542.s10.e0" /><pair ddi="false" e1="DDI-PubMed.25789542.s10.e0" e2="DDI-PubMed.25789542.s10.e1" /><pair ddi="false" e1="DDI-PubMed.25789542.s10.e0" e2="DDI-PubMed.25789542.s10.e2" /><pair ddi="false" e1="DDI-PubMed.25789542.s10.e1" e2="DDI-PubMed.25789542.s10.e1" /><pair ddi="false" e1="DDI-PubMed.25789542.s10.e1" e2="DDI-PubMed.25789542.s10.e2" /></sentence><sentence text=" In conclusion, aspirin medication prior to dipyrone intake preserves antiplatelet effects, circumventing the pharmacodynamic drug-drug interaction at the level of cyclooxygenase-1"><entity charOffset="16-23" id="DDI-PubMed.25789542.s11.e0" text="aspirin" /><entity charOffset="44-52" id="DDI-PubMed.25789542.s11.e1" text="dipyrone" /><pair ddi="false" e1="DDI-PubMed.25789542.s11.e0" e2="DDI-PubMed.25789542.s11.e0" /><pair ddi="false" e1="DDI-PubMed.25789542.s11.e0" e2="DDI-PubMed.25789542.s11.e1" /></sentence><sentence text=" " /></document>